The Hong Kong team was led by Counsel Vincent Chan.
YHLO Biotech is a leading company of immunoassay solutions in China, specialised in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents for diagnosis of autoimmune diseases, reproductive health, infectious diseases and others. It was founded in 2008 and is headquartered in Shenzhen China.
Vincent commented “As a leading specialist in Hong Kong for offshore initial public offerings work, this deal further demonstrates our expertise and capability in helping clients with their listings in Asia.”
Our Hong Kong Capital Markets team is highly regarded for their extensive expertise in supporting offshore companies with IPOs, introductions, placements and listings of both equity and debt securities on the Hong Kong, US, Singapore and many other internationally recognised stock exchanges.
